<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81727">
  <stage>Registered</stage>
  <submitdate>29/11/2006</submitdate>
  <approvaldate>12/02/2007</approvaldate>
  <actrnumber>ACTRN12607000124437</actrnumber>
  <trial_identification>
    <studytitle>Safety and Efficacy of BG00012 in Relapsing Remitting Multiple Sclerosis</studytitle>
    <scientifictitle>A Randomized, Multicentre, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Safety and Efficacy of BG00012 in Subjects with Relapsing Remitting Multiple Sclerosis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Biogen Idec: 109MS301</secondaryid>
    <secondaryid>European Union Clinical Trials Database (EUDRACT): 2006-003696-12</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Multiple Sclerosis (Relapsing Remitting)</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Multiple sclerosis</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>BG00012; Group 1 will receive 480 mg daily orally via 2 capsules 3 times daily. Each capsule will contain either 120 mg BG00012 or placebo (lactose monohydrate). Group 2 will receive 720 mg daily orally via 2 capsules 3 times daily. Each capsule will contain 120 mg BG00012.
Treatment will be for 2 years.</interventions>
    <comparator>Group 3 will receive placebo capsules (containing lactose monohydrate) orally via 2 capsules 3 times daily.
Treatment will be for 2 years.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Proportion of relapsing subjects compared between BG00012 treatment groups and placebo group</outcome>
      <timepoint>At 2 years </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Annual relapse rate, rate of disability progression as measured by MSFC; (In a subset of patients: new or enlarging T2 hyperintense lesions, Gd-enhancing lesions and T1 hypointense lesions on brain MRI).</outcome>
      <timepoint>At 1 year</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome> Disability Progression as measured by EDSS and MSFC; (In a subset of patients: volume of T2 hyperintense and T1 hypointense lesions on brain MRI).</outcome>
      <timepoint>At 2 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Confirmed diagnosis of relapsing remitting multiple sclerosis according to McDonald criteria #1-4At least 1 relapse within 12 months prior to randomization with cranial MRI demonstrating MS consistent lesions, OR evidence of Gadolinium enhancing brain lesions on MRI within 6 weeks prior to randomisationBaseline Expanded Disability Status Score (EDSS) between 0.0 and 5.0.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Primary progressive, secondary progressive or progressive relapsing Multiple SclerosisAn MS relapse within 50 days of randomisation OR a patient who has not stabilised from a previous relapse prior to randomisationInability to perform Timed 25-Foot Walk, Nine-Hole Peg Test (9HPT) with both upper extremities, PASAT 3, or Visual Function testHistory of MalignancyHistory of severe allergic or anaphylactic reactions/known drug hypersensitivityHistory of HIVHistory of Drug or Alcohol abuse in last 2 yearsPositive for Hep C antibody and/or Hep B surface antigenAbnormal laboratory results indicative of major disease which would preclude clinical trial participationAny previous treatment with FUMADERM or BG00012/FAG-201History of other disallowed medication use outside of the time-frames specified in the protocolWomen of child-bearing potential not using adequate contraceptionEnrolment in other clinical trials within 6 months prior to randomisation.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation via phone/fax/computer</concealment>
    <sequence>Computerised randomisation</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>All subjects, physicians, data analysts and assessors will be blinded to subject's treatment.</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>15/12/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1011</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen Idec</primarysponsorname>
    <primarysponsoraddress>Thames House, 5 Roxborough Way, Maidenhead, Berks SL6 3UD, United Kingdom</primarysponsoraddress>
    <primarysponsorcountry>United Kingdom</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Biogen Idec</fundingname>
      <fundingaddress>Thames House, 5 Roxborough Way, Maidenhead, Berks SL6 3UD, United Kingdom</fundingaddress>
      <fundingcountry>United Kingdom</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of the study is to determine whether BG00012 is effective in reducing the proportion of patients experiencing a clinical relapse at 2 years compared to placebo in patients with relapsing remitting multiple sclerosis. Two different doses of BG00012 will be compared to placebo.
Patients will be randomised to one of 3 groups in a 1:1:1 ratio:
Group 1 will receive 480 mg daily orally via 2 capsules 3 times daily. Each capsule will contain either 120 mg BG00012 or placebo.
Group 2 will receive 720 mg daily orally via 2 capsules 3 times daily. Each capsule will contain 120 mg BG00012.
Group 3 will receive placebo orally via 2 capsules 3 times daily.
Patients will have the option of switching to open label Avonex (interferon beta-1a) if they experience relapse after 24 weeks and have completed 48 weeks of double blind treatment, OR they experience disability progression sustained for 12 weeks at any time.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress>Camperdown, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress>Melbourne, VIC</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>John Hunter Hospital</ethicname>
      <ethicaddress>Newcastle, NSW</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Karen Smith</name>
      <address>C/O Biogen Idec Australia Pty Ltd
PO Box 380
North Ryde  BC
NSW   1670</address>
      <phone>02 8875 3915</phone>
      <fax>02 9889 1162</fax>
      <email>Karen.smith@biogenidec.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Prof John Pollard</name>
      <address>Department of Medicine, Blackburn Building, University of Sydney, NSW 2006</address>
      <phone>61 2 9351 3385</phone>
      <fax>61 9 9351 4018</fax>
      <email>jdpoll@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>